HL Pharma shares pharmaceutical news, industry updates and practical guidance for sponsors, healthcare providers and supply partners across Australia.
Stricter storage, cold-chain and governance rules mean clinical trial, Managed Access and Early Access medicines now rely on specialist depots across Australia and APAC.
read moreAt HL Pharma, packaging is a critical control point, not just a box around your product. Our validated solutions for +2 °C to +8 °C, +15 °C to +25 °C and below −20 °C combine qualified shippers, reusable and recyclable options, real-time temperature monitoring.
read moreTransdermal scopolamine is an unregistered medicine in Australia. Access is available exclusively to healthcare professionals through the TGA Special Access Scheme (SAS) where clinically appropriate and when no suitable registered alternative exists.
read moreThe storage and distribution of clinical trial materials is one of the most demanding aspects of modern pharmaceutical research, requiring precision, compliance, and collaboration across the supply chain.
read moreHL Pharma is proud to announce that we will be exhibiting at the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) Congress 2025, taking place in Melbourne this November.
read moreThis October, HL Pharma is proud to be attending CPHI Frankfurt 2025, the world’s leading pharmaceutical event. With more than 62,000 industry professionals and 2,400 exhibitors, CPHI brings together every part of the global pharmaceutical supply chain.
read more
